Table 4.
Pharmacokinetic parameters of gliclazide in subjects with various CYP2C19 genotypes in the single-dose study (mean and 95% CI)
| Parameters | CYP2C19*1 homozygotes (n = 9) | CYP2C19*1 heterozygotes (n = 12) | CYP2C19 poor metabolizers (n = 3) |
|---|---|---|---|
| AUC0−72 (µg ml−1 h−1) | 21.5 (15.4, 27.6) | 26.4 (18.9, 33.8) | 50.7 (21.5, 79.8)* |
| AUC0–∞ (µg ml−1 h−1) | 22.7 (15.9, 29.5) | 28.4 (20.0, 36.9) | 77.6 (14.2, 141.1)** |
| Cmax (µg ml−1) | 1.16 (0.75, 1.56) | 1.20 (0.79, 1.61) | 1.48 (0.09, 2.87) |
| tmax (h) | 8.67 (7.30, 10.0) | 9.83 (8.25, 11.4) | 10.7 (4.93, 16.4) |
| t1/2 (h) | 15.1 (11.2, 18.9) | 17.4 (15.5, 19.2) | 44.5 (6.12, 82.8)** |
*
P < 0.05
**
P < 0.01, compared with CYP2C19*1 homozygotes.